vs
Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Beam Therapeutics Inc. (BEAM). Click either name above to swap in a different company.
BIOCRYST PHARMACEUTICALS INC is the larger business by last-quarter revenue ($406.6M vs $114.1M, roughly 3.6× Beam Therapeutics Inc.). Beam Therapeutics Inc. runs the higher net margin — 214.1% vs 60.5%, a 153.6% gap on every dollar of revenue. On growth, Beam Therapeutics Inc. posted the faster year-over-year revenue change (279.5% vs 209.1%). BIOCRYST PHARMACEUTICALS INC produced more free cash flow last quarter ($291.2M vs $-87.0M).
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.
BCRX vs BEAM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $406.6M | $114.1M |
| Net Profit | $245.8M | $244.3M |
| Gross Margin | 97.7% | — |
| Operating Margin | 64.0% | -15.3% |
| Net Margin | 60.5% | 214.1% |
| Revenue YoY | 209.1% | 279.5% |
| Net Profit YoY | 1017.5% | 370.4% |
| EPS (diluted) | $1.13 | $2.53 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $406.6M | $114.1M | ||
| Q3 25 | $159.4M | — | ||
| Q2 25 | $163.4M | — | ||
| Q1 25 | $145.5M | — | ||
| Q4 24 | $131.5M | — | ||
| Q3 24 | $117.1M | — | ||
| Q2 24 | $109.3M | — | ||
| Q1 24 | $92.8M | — |
| Q4 25 | $245.8M | $244.3M | ||
| Q3 25 | $12.9M | — | ||
| Q2 25 | $5.1M | — | ||
| Q1 25 | $32.0K | — | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $-14.0M | — | ||
| Q2 24 | $-12.7M | — | ||
| Q1 24 | $-35.4M | — |
| Q4 25 | 97.7% | — | ||
| Q3 25 | 98.6% | — | ||
| Q2 25 | 98.3% | — | ||
| Q1 25 | 96.9% | — | ||
| Q4 24 | 95.4% | — | ||
| Q3 24 | 97.3% | — | ||
| Q2 24 | 98.4% | — | ||
| Q1 24 | 98.6% | — |
| Q4 25 | 64.0% | -15.3% | ||
| Q3 25 | 18.6% | — | ||
| Q2 25 | 18.2% | — | ||
| Q1 25 | 14.6% | — | ||
| Q4 24 | -3.4% | — | ||
| Q3 24 | 6.6% | — | ||
| Q2 24 | 8.0% | — | ||
| Q1 24 | -15.6% | — |
| Q4 25 | 60.5% | 214.1% | ||
| Q3 25 | 8.1% | — | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | -20.4% | — | ||
| Q3 24 | -12.0% | — | ||
| Q2 24 | -11.6% | — | ||
| Q1 24 | -38.1% | — |
| Q4 25 | $1.13 | $2.53 | ||
| Q3 25 | $0.06 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | — | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | $-0.07 | — | ||
| Q2 24 | $-0.06 | — | ||
| Q1 24 | $-0.17 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $274.7M | $1.2B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-119.2M | $1.2B |
| Total Assets | $514.2M | $1.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $274.7M | $1.2B | ||
| Q3 25 | $212.9M | — | ||
| Q2 25 | $260.0M | — | ||
| Q1 25 | $295.1M | — | ||
| Q4 24 | $320.9M | — | ||
| Q3 24 | $96.8M | — | ||
| Q2 24 | $78.4M | — | ||
| Q1 24 | $84.3M | — |
| Q4 25 | $-119.2M | $1.2B | ||
| Q3 25 | $-387.9M | — | ||
| Q2 25 | $-421.6M | — | ||
| Q1 25 | $-451.9M | — | ||
| Q4 24 | $-475.9M | — | ||
| Q3 24 | $-468.6M | — | ||
| Q2 24 | $-475.6M | — | ||
| Q1 24 | $-476.2M | — |
| Q4 25 | $514.2M | $1.5B | ||
| Q3 25 | $446.4M | — | ||
| Q2 25 | $457.2M | — | ||
| Q1 25 | $480.0M | — | ||
| Q4 24 | $490.4M | — | ||
| Q3 24 | $491.3M | — | ||
| Q2 24 | $472.4M | — | ||
| Q1 24 | $467.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $292.0M | $-83.3M |
| Free Cash FlowOCF − Capex | $291.2M | $-87.0M |
| FCF MarginFCF / Revenue | 71.6% | -76.3% |
| Capex IntensityCapex / Revenue | 0.2% | 3.3% |
| Cash ConversionOCF / Net Profit | 1.19× | -0.34× |
| TTM Free Cash FlowTrailing 4 quarters | $344.9M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $292.0M | $-83.3M | ||
| Q3 25 | $41.6M | — | ||
| Q2 25 | $41.3M | — | ||
| Q1 25 | $-27.5M | — | ||
| Q4 24 | $-5.2M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.4M | — | ||
| Q1 24 | $-53.7M | — |
| Q4 25 | $291.2M | $-87.0M | ||
| Q3 25 | $40.3M | — | ||
| Q2 25 | $41.1M | — | ||
| Q1 25 | $-27.7M | — | ||
| Q4 24 | $-5.9M | — | ||
| Q3 24 | $8.2M | — | ||
| Q2 24 | $-1.5M | — | ||
| Q1 24 | $-53.9M | — |
| Q4 25 | 71.6% | -76.3% | ||
| Q3 25 | 25.3% | — | ||
| Q2 25 | 25.2% | — | ||
| Q1 25 | -19.0% | — | ||
| Q4 24 | -4.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | -1.4% | — | ||
| Q1 24 | -58.1% | — |
| Q4 25 | 0.2% | 3.3% | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 1.19× | -0.34× | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCRX
Segment breakdown not available.
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
